Navigation Links
Novel compounds show promise as safer, more potent insecticides

Research teams at Nihon Nohyaku Co., Ltd., Bayer CropScience and DuPont have developed two new classes of broad-spectrum insecticides that show promise as a safer and more effective way to fight pest insects that damage food crops. The insecticides, which represent the first synthetic compounds designed to activate a novel insecticide target called the ryanodine receptor, may also help tackle the growing problem of insecticide resistance, the researchers say. They described their studies today at the 230th national meeting of the American Chemical Society, the world’s largest scientific society.

Many of the most widely used insecticides today act on only a handful of exploited targets, including the organophosphates, which block acetylcholinesterase, an enzyme that helps control nerve activity. Some experts are concerned that these older, less-selective insecticides could pose heath risks and there’s a growing effort underway to find safer replacements.

Targeting the ryanodine receptor may offer a promising alternative, researchers say. Ryanodine, a natural alkaloid discovered years ago in a species of tropical plant, has been used to study muscle physiology in a wide variety of organisms, including insects and mammals. Ryanodine receptors regulate muscle and nerve activities by modifying levels of internal calcium in these cells. These receptors exist in both mammals and insects but have distinct differences. Researchers have known that ryanodine itself has insecticidal properties, but no synthetic molecules had previously been identified that potently and selectively target these receptors in insects, until now.

Nihon Nohyaku Co., Ltd., based in Japan, and Bayer CropScience AG in Germany have jointly developed Flubendiamide, the first example of the phthalic acid diamides, a novel class of insecticides that activate the ryanodine receptor. The insecticide is highly effective against many different species of caterpillars, says Masanori Tohni shi, a senior research scientist at Nihon Nohyaku. In early tests, the compound showed high activity against the tobacco budworm (Heliothis virescens), which is known to cause serious damage to cotton, tobacco and other crops, the researchers say. The compound did not have any measurable effect on mammalian ryanodine receptors, according to Peter Lümmen, Ph.D., a research scientist at Bayer CropScience.

DuPont, based in Wilmington, Del., is developing another group of compounds that target the ryanodine receptor. Called anthranilic diamides, these novel compounds show excellent control of pest insects with exceptional mammalian safety, according to the researchers. They were the first to demonstrate the mode of action of these ryanodine receptor-active molecules, says Daniel Cordova, a researcher at DuPont Crop Protection.

Both classes of compounds are believed to have high potency, the researchers say, although they are structurally different. Both insecticides are still in developmental stages.

The research team at DuPont says they have cloned ryanodine receptors from several insect species and that these receptors may help provide a better understanding of their role in calcium signaling, which could lead to new insights into human diseases.

The American Chemical Society is a nonprofit organization, chartered by the U.S. Congress, with a multidisciplinary membership of more than 158,000 chemists and chemical engineers. It publishes numerous scientific journals and databases, convenes major research conferences and provides educational, science policy and career programs in chemistry. Its main offices are in Washington, D.C., and Columbus, Ohio.


'"/>

Source:American Chemical Society


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel technology detects human DNA mutations
3. Novel antiviral technology inhibits RSV infection in mice
4. Novel Enzyme Shows Potential As An Anti-HIV Target
5. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
6. Discovery Could Lead To Novel Approaches In HIV Treatment
7. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
8. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
9. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
10. Novel live reporting system to track cells
11. Field of beams - Novel system uses polarized light pulses to reveal crop health
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology: